Biotechnology company
Appears in 1 story · Last updated Nov 22, 2026
Sponsor of deramiocel; rejected twice by the FDA
Deramiocel was built to slow the heart and muscle damage that makes Duchenne muscular dystrophy fatal. On Friday the Food and Drug Administration turned it down for the second time in 16 months, and this rejection did not hinge on whether the benefit was big enough. The agency said the trial data could not be trusted.
Updated 56 minutes ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?